We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Evotec Enters into Integrated Drug Discovery Alliance with Genentech


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Enters into Integrated Drug Discovery Alliance with Genentech"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
Evotec AG has announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group, to discover novel small molecule therapeutics.

Evotec will apply its integrated drug discovery platform in combination with its extensive disease biology expertise against targets nominated by Genentech. This will include assay development and high throughput screening, medicinal chemistry and structural biology. The aim of the collaboration is to deliver high quality leads and development candidates to support Genentech’s research efforts.

Further commercial details were not released.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are proud that Genentech, one of the premier biopharmaceutical companies worldwide, has selected Evotec’s scientists and innovative drug discovery platform to support their research efforts. We look forward to working closely with Genentech’s scientists and achieving success together.”
Advertisement